TheraCIM hR3: Phase I/II data

In a Cuban Phase I/II trial in 24 patients, TheraCIM hR3 was well tolerated at 6 weekly infusions of 50-400 mg in combination with radiation therapy. Data were published in the Journal of Clinical Onc...